These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 10949395)

  • 1. Prognostic significance of deletion and over-expression of the p53 gene in epithelial ovarian cancer.
    Ozalp SS; Yalcin OT; Basaran GN; Artan S; Kabukcuoglu S; Minsin TH
    Eur J Gynaecol Oncol; 2000; 21(3):282-6. PubMed ID: 10949395
    [TBL] [Abstract][Full Text] [Related]  

  • 2. p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
    Laframboise S; Chapman W; McLaughlin J; Andrulis IL
    Cancer J; 2000; 6(5):302-8. PubMed ID: 11079169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Misregulation of polo-like protein kinase 1, P53 and P21WAF1 in epithelial ovarian cancer suggests poor prognosis.
    Zhang R; Shi H; Ren F; Liu H; Zhang M; Deng Y; Li X
    Oncol Rep; 2015 Mar; 33(3):1235-42. PubMed ID: 25592872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic impact of p53, p27, and C-MYC on clinicopathological features and outcome in early-stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir IA; Sorbe B; Lindborg K; Seidal T
    Int J Gynecol Cancer; 2011 Feb; 21(2):236-44. PubMed ID: 21270607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
    Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
    Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
    [No Abstract]   [Full Text] [Related]  

  • 6. Stomatin-like protein 2 is overexpressed in epithelial ovarian cancer and predicts poor patient survival.
    Sun F; Ding W; He JH; Wang XJ; Ma ZB; Li YF
    BMC Cancer; 2015 Oct; 15():746. PubMed ID: 26487491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
    Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
    J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Havrilesky L; Darcy kM; Hamdan H; Priore RL; Leon J; Bell J; Berchuck A;
    J Clin Oncol; 2003 Oct; 21(20):3814-25. PubMed ID: 14551300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunohistochemically detected p53 mutations in epithelial tumors and results of treatment with chemotherapy and radiotherapy. A treatment-specific overview of the clinical data.
    Thames HD; Petersen C; Petersen S; Nieder C; Baumann M
    Strahlenther Onkol; 2002 Aug; 178(8):411-21. PubMed ID: 12240546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
    Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
    Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
    Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
    Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantification of p53 in epithelial ovarian cancer.
    Geisler JP; Geisler HE; Wiemann MC; Givens SS; Zhou Z; Miller GA
    Gynecol Oncol; 1997 Sep; 66(3):435-8. PubMed ID: 9299258
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic impact of concomitant p53 and PTEN on outcome in early stage (FIGO I-II) epithelial ovarian cancer.
    Skírnisdóttir I; Seidal T
    Int J Gynecol Cancer; 2011 Aug; 21(6):1024-31. PubMed ID: 21792012
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BubR1 as a prognostic marker for recurrence-free survival rates in epithelial ovarian cancers.
    Lee YK; Choi E; Kim MA; Park PG; Park NH; Lee H
    Br J Cancer; 2009 Aug; 101(3):504-10. PubMed ID: 19603021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of tissue protein expression levels of MIB-1 (Ki-67) in Danish ovarian cancer patients. From the 'MALOVA' ovarian cancer study.
    Heeran MC; Høgdall CK; Kjaer SK; Christensen L; Jensen A; Blaakaer J; Christensen IJ; Høgdall EV
    APMIS; 2013 Dec; 121(12):1177-86. PubMed ID: 23594232
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic significance of p53 immunostaining in epithelial ovarian cancer.
    Hartmann LC; Podratz KC; Keeney GL; Kamel NA; Edmonson JH; Grill JP; Su JQ; Katzmann JA; Roche PC
    J Clin Oncol; 1994 Jan; 12(1):64-9. PubMed ID: 8270986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic significance of p53 tumor suppressor gene alterations in ovarian carcinoma.
    Shahin MS; Hughes JH; Sood AK; Buller RE
    Cancer; 2000 Nov; 89(9):2006-17. PubMed ID: 11064359
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer.
    Shimogai R; Kigawa J; Itamochi H; Iba T; Kanamori Y; Oishi T; Shimada M; Sato S; Kawaguchi W; Sato S; Terakawa N
    Int J Gynecol Cancer; 2008; 18(3):499-505. PubMed ID: 18476949
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathological values of NBS1 and DNA damage response genes in epithelial ovarian cancers.
    Lee YK; Park NH; Lee H
    Exp Mol Med; 2015 Nov; 47(11):e195. PubMed ID: 26584681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of the cyclin-dependent kinase inhibitor p21Cip1 in epithelial ovarian tumors of low malignant potential and adenocarcinomas.
    Vassilopoulos I; Korkolopoulou P; Konstantinidou AE; Patsouris E; Eftichiadis C; Thymara I; Perdiki M; Pavlakis K; Agapitos E; Davaris PS
    Histol Histopathol; 2003 Jul; 18(3):761-70. PubMed ID: 12792888
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.